[Pharmacotherapy for degenerative dementias].
Alzheimer disease is the most frequent type of dementia. The pathophysiology is now better understood and new drugs or therapeutic tools have been developed. Anticholinesterase and antiglutamatergic drugs are used for a few years but these drugs have a modest therapeutic efficacy, which is purely symptomatic. New drugs are in development, including neuroprotection and prevention. Taking into account the experience of these last years, several aspects have to be discussed or improved: ethical aspects, risk evaluation and cost of the treatments, biological markers of pre-symptomatic phase, well conducted clinical trials and comparative studies between different drugs, evaluation of the effective clinical results of the studies.
Maloteaux
J M
JM
D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy*; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use
D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents